TSO3 third quarter revenue decreases from $126,162 to $122,759

NewsGuard 100/100 Score

Highlights of Q3 2010 and recent weeks:

  • Adopted process improvement initiatives in support of 3M™ quality policies;
  • Successfully recruited Senior Engineering and Supply Chain talent into the Company;
  • Received commitments for additional sterilizers to be delivered in 2011;
  • Met with US regulators and subsequently supplied formal background documentation, including additional safety and efficacy documentation.

TSO3 Inc. ("TSO3") (TSX: TOS) an innovator in sterilization technology for medical devices in healthcare settings using ozone, posted revenues of $122,759 for the third quarter of 2010, ended September 30, for the sale of accessories and service contracts. This compares to $126,162 for the same period in 2009, for the sale of accessories and service contracts as well. The Company recorded a net loss of $2,033,140 for the third quarter of 2010, or $0.04 per share, compared to a net loss of $2,287,711 or $0.05 for the same period in 2009.

For the nine-month period ending September 30, 2010, the net loss amounted to $5,973,837, or $0.11 per share, compared to $6,538,518, or $0.14 per share for the same period in 2009.

"In third quarter, TSO3 continued the process of transitioning from a direct, regional entity, to a technology focused organization, global in scope", said R.M. (Ric) Rumble President and CEO of TSO3. "We are now building sterilizers bearing the 3M™ brand and we are expected to build and support to 3M's specifications and processes. In order to do that, a number of process initiatives have been adopted over the recent months and continue. With 3M's support, we are maturing as an organization at high speed and all lessons we learn will be applied to our new projects", added Mr. Rumble.

"In the meantime, we continue to experience interest for the product and backlog increases for shipments in 2011. As for our filing for US regulatory clearance, we have supplied a first round of documents to the Agency during the quarter and remain in open dialogue with the regulators for an eventual filing", concluded Mr. Rumble.

Source:

TSO3 INC.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The efficacy of the Mediterranean diet on health outcomes in adults with cancer